A Multi-center, Phase 1, Open-label Evaluation Of The Effect Of Pf-00547659 (Anti Madcam Monoclonal Antibody) On The Cerebrospinal Fluid (Csf) Lymphocytes In Volunteers With Crohn's Disease Or Ulcer Ulcerative Colitis Who Are Anti-tnf Inadequate Responders (Tosca)

Trial Profile

A Multi-center, Phase 1, Open-label Evaluation Of The Effect Of Pf-00547659 (Anti Madcam Monoclonal Antibody) On The Cerebrospinal Fluid (Csf) Lymphocytes In Volunteers With Crohn's Disease Or Ulcer Ulcerative Colitis Who Are Anti-tnf Inadequate Responders (Tosca)

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs PF-547659 (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Pharmacodynamics
  • Acronyms TOSCA
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Jun 2016 Results published in a Shire media release.
    • 21 Jan 2016 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 27 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Nov 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top